What Happened
- A study has found that India and China top the Asia-Pacific region in terms of the burden of metabolic diseases, measured in DALYs (Disability-Adjusted Life Years) and deaths.
- In 2023, India recorded approximately 21 million DALYs and 5.8 lakh deaths attributable to type 2 diabetes — among the highest globally.
- High systolic blood pressure (hypertension) caused nearly 3.8 crore (38 million) DALYs and approximately 15.7 lakh deaths in India in the same period.
- Metabolic diseases — which include type 2 diabetes, hypertension, obesity, dyslipidaemia (abnormal blood lipids), and chronic kidney disease — are increasingly recognised as a cluster driven by shared risk factors including poor diet, sedentary lifestyles, and urbanisation.
- The findings align with the Global Burden of Disease (GBD) data: hypertension globally caused 226 million DALYs in 2021, while type 2 diabetes caused 75 million DALYs — making them among the most burdensome non-communicable diseases worldwide.
- Both India and China face a "double burden" — the persistence of infectious diseases alongside a rapid rise in non-communicable diseases (NCDs) — compounded by ageing populations and urbanisation.
Static Topic Bridges
DALYs — The Standard Measure of Disease Burden
A Disability-Adjusted Life Year (DALY) is the primary metric used by the World Health Organization (WHO) and the Institute for Health Metrics and Evaluation (IHME) to quantify the overall burden of disease. One DALY represents one year of healthy life lost.
- DALY = YLL (Years of Life Lost to premature death) + YLD (Years Lived with Disability).
- DALYs allow comparison across very different diseases and populations, enabling policymakers to prioritise interventions by disease burden.
- The Global Burden of Disease (GBD) study, coordinated by IHME at the University of Washington, is the most comprehensive global effort to quantify DALYs.
- WHO uses DALYs in its Global Health Estimates to compare country and regional disease burdens annually.
- India-specific DALY data is critical for the National Health Policy and the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD).
Connection to this news: The 21 million DALYs from type 2 diabetes and 38 million from hypertension in India are not abstract statistics — they translate directly into years of productive life lost, healthcare expenditure, and economic output foregone, making them a governance challenge as much as a health challenge.
Non-Communicable Diseases (NCDs) and India's Epidemiological Transition
India is undergoing an epidemiological transition — a shift in the dominant causes of death and disability from communicable diseases (infections, malnutrition) to non-communicable diseases (heart disease, diabetes, cancer, chronic respiratory disease). NCDs now account for approximately 63% of all deaths in India.
- The four major NCDs — cardiovascular disease, cancer, chronic respiratory disease, and diabetes — together account for about 60% of India's NCD burden.
- India has an estimated 10.1 crore (101 million) people living with diabetes — the second-largest diabetic population globally after China.
- Hypertension affects approximately 21.4 crore (214 million) Indians, with over 50% unaware of their condition.
- Risk factors: high salt intake, low physical activity, tobacco use, unhealthy diet, air pollution, and stress — all amplified by rapid urbanisation.
- India's NCD burden disproportionately affects working-age adults (30–69 years), unlike developed countries where NCDs are predominantly a disease of old age.
Connection to this news: India topping the Asia-Pacific in metabolic disease burden is a direct consequence of this epidemiological transition, aggravated by the scale of India's population and the pace of its urbanisation.
Metabolic Syndrome — Concept and Policy Relevance
Metabolic syndrome refers to the co-occurrence of multiple metabolic risk factors — central obesity, high blood pressure, high blood sugar, high triglycerides, and low HDL cholesterol — in the same individual. Presence of any three of these five constitutes metabolic syndrome.
- Metabolic syndrome is not a single disease but a cluster of conditions that significantly increases risk of cardiovascular disease, type 2 diabetes, stroke, and chronic kidney disease.
- Prevalence of metabolic syndrome in India is estimated at 25–40% of urban adults and rising in rural areas.
- Asian populations, including Indians and Chinese, develop metabolic syndrome at lower BMI thresholds than Western populations — a population-specific risk factor.
- India-specific BMI cut-offs for obesity are lower: overweight is defined as BMI ≥23 kg/m², obesity as BMI ≥25 kg/m² (vs. 25 and 30 respectively in Western guidelines).
Connection to this news: The clustering of metabolic diseases in India and China reflects the epidemiology of metabolic syndrome. Policy responses must address the full cluster — not just diabetes or hypertension in isolation — through integrated lifestyle interventions and universal screening.
Government Response — Ayushman Bharat and NCD Prevention
India's flagship health schemes address the NCD burden through prevention, early detection, and treatment. The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Disease, and Stroke (NPCDCS) is the primary platform, now integrated into the Ayushman Bharat Health and Wellness Centres (HWCs).
- Ayushman Bharat PM-JAY provides insurance coverage of up to ₹5 lakh per family per year for hospitalisation, including NCD treatment.
- Health and Wellness Centres (HWCs) — 1.5 lakh planned — offer free NCD screening at the primary care level, including blood pressure and blood sugar testing.
- India committed to the WHO Global Action Plan for NCDs 2013–2030: 30% reduction in premature NCD mortality and 33% reduction in hypertension prevalence by 2030.
- The Eat Right India and Fit India missions target dietary change and physical activity as upstream determinants of metabolic disease.
Connection to this news: Despite these programmes, the scale of India's metabolic disease burden — as quantified in DALYs — indicates that current interventions are insufficient to reverse the trend. The data strengthens the case for expanding HWC-based screening and accelerating NCD policy implementation.
Key Facts & Data
- India's type 2 diabetes DALYs in 2023: approximately 21 million.
- India's type 2 diabetes deaths in 2023: approximately 5.8 lakh.
- India's hypertension DALYs in 2023: approximately 3.8 crore (38 million).
- India's hypertension deaths in 2023: approximately 15.7 lakh.
- India's estimated diabetic population: approximately 10.1 crore (101 million) — second globally after China.
- India's estimated hypertension burden: approximately 21.4 crore (214 million) affected.
- Global hypertension DALYs (2021): 226 million (highest among metabolic diseases).
- Global type 2 diabetes DALYs (2021): 75 million.
- NCDs account for approximately 63% of all deaths in India.
- India-specific obesity threshold: BMI ≥25 kg/m² (vs. ≥30 in Western guidelines).
- India committed to WHO Global Action Plan for NCDs 2013–2030: 30% reduction in premature NCD mortality by 2030.